STERIS (STE): A Quality Business Hindered by Price and Weaker Technicals

At first glance, STERIS appears to be a textbook example of a quality healthcare company: revenues are growing, net margins are improving, free cash flow remains positive, and the Piotroski F-Score is 8 out of 9. However, the overall QMA score is only 61.5, while the fundamental pillar FVS reaches 91.4. The paradox is clear: operational data looks stronger than the resulting investment picture.

Thesis

STERIS plc (STE), a company in the Healthcare / Medical - Specialties sector with a market capitalization of $24.38 billion, stands at the intersection between a quality defensive business and a stock that the market already values quite highly. The QMA Brain thesis is therefore descriptive: the company's fundamentals are significantly better than its overall score because weaker technicals, expensive valuation according to selected multiples, and low capital returns dampen an otherwise strong picture.

This is not a story of a company that is clearly failing operationally. The last reported period Q4 2026-03-31 shows revenues of $1.59 billion, year-over-year revenue growth of 7.3%, a gross margin of 43.9%, an operating margin of 19.9%, and a net margin of 13.9%. These are numbers that signal the ability to sell with decent profitability. The problem lies elsewhere: P/E is 110.7, P/S 15.35, and FCF yield only 1%. In other words, the market pays a high price for every dollar of current cash flow.

What the Numbers Say

Let's start with the quality of the report. In the last period, STERIS generated operating cash flow of $335.4 million and free cash flow of $245.2 million. Free cash flow is the cash that remains after operating and capital expenditures; for beginners, it is one of the most important metrics because accounting profit can be affected by non-cash items, while cash flow shows how much money actually flowed into the company.

Net income was $220.3 million, and diluted EPS reached 2.24. This means the company is profitable not only at the revenue level but also after deducting costs, taxes, and other items. A net margin of 13.9% indicates that approximately thirteen cents of net profit remain from every dollar of revenue after all costs. Additionally, an operating margin of 19.9% shows that the core business yields even higher profitability before some non-operating items.

The trend over periods is important for a bullish interpretation. Revenues increased from $1.28 billion in Q1 2024-06-30 to $1.59 billion in Q4 2026-03-31. The net margin in the same sequence moved from 11.4% to 13.9%, although it fluctuated in between, for example, to 9.8% in Q4 2025-03-31. Free cash flow was positive in all mentioned periods: from $148.9 million in Q2 2024-09-30 to $326.4 million in Q1 2025-06-30. The latest $245.2 million is not a one-time spike from zero but a continuation of a longer ability to generate cash.

The financial profile is also strong. Debt/Equity is 0.02, indicating very low leverage relative to equity. Altman Z-Score of 5.39 shows a healthier financial position according to a model that historically tracks the risk of financial distress. Piotroski F-Score of 8 out of 9 complements the picture of a company with quality accounting and operational characteristics.

But here comes the brake. ROIC is only 4.4% and ROE 3.1%. ROIC measures the return on capital employed in the business; for a quality company, the market would typically prefer this metric to be higher. Low ROIC and ROE do not say the company is not making money. They rather indicate that given the capital tied up in the company, the return is not as high as the margins alone might suggest.

The second brake is the price. P/E of 110.7 is a very demanding earnings multiple. P/S of 15.35 means the market values the company at more than fifteen times its revenues. FCF yield of 1% then shows that free cash flow is low relative to market capitalization. The QMA model also reports a deviation from the model fair value of -10.6%, where a positive number indicates room for growth. Here the number is negative, so the model does not see the stock as cheap relative to its fair value.

Bullish Scenario

The optimistic interpretation begins with the fact that operational development is more stable than the overall score. Revenues gradually increased from $1.28 billion to $1.59 billion, and the latest year-over-year growth of 7.3% shows that demand for the company's services and products is still growing. In the Healthcare / Medical - Specialties sector, such a combination of growth, margins, and low leverage is data-attractive.

The bullish view is also strengthened by the quality of earnings. EQS is 88, catalysts/earnings score XS is 84, and FVS is 91.4. This means the QMA pillars rate the fundamental side very highly. The company has a gross margin of 43.9%, an operating margin of 19.9%, and a net margin of 13.9%, so it's not just growth without profitability. Each period in the provided time series also showed positive FCF.

Another supporting point is the stable number of shares. The trend in the number of shares is marked as stable, so the data does not show significant shareholder dilution. Combined with low Debt/Equity of 0.02, this is a more conservative financial profile that can give the company flexibility in a worse macro environment.

Publicly reported insider activity over approximately 90 days also has a positive effect. Purchases reached $40.9 million from 18 insiders, while sales were $5.5 million from 11 insiders. Insider activity is not in itself proof of future development, but in the data, it creates a signal that some insiders were willing to increase exposure at the current valuation.

Bearish Scenario

The pessimistic interpretation is mainly based on the fact that the quality of the company does not automatically mean an attractive stock valuation. P/E of 110.7, P/S of 15.35, and FCF yield of 1% together say that the market values STERIS very premiumly. If revenue growth of 7.3% or a net margin of 13.9% does not continue in future periods, the valuation could appear tight.

The second weakness is the return on capital. ROIC of 4.4% and ROE of 3.1% are low compared to how expensive the stock looks according to multiples. This is an important distinction: a company can have good margins, but if a large part of the capital does not generate sufficient returns, long-term compounding may be weaker than the revenue growth alone would suggest.

The third brake is the technical picture. TSS is 46.7, below the neutral level of 50. Relative strength RS is 52, which is only slightly above the middle of the scale. The price has increased by 2.8% over the last approximately 30 days and by about 11.3% over roughly 90 days, but it is still 11.9% below the 52-week high. This shows that while the stock has rebounded, the technical pillar does not yet confirm as strong a story as the fundamentals.

The institutional flow is also mixed. Reported quarterly positions are published with a delay of approximately 45 days, so it is not a current real-time picture. For the quarter ending 2026-06-30, 823 institutions were reported, a change of -22. There were 109 new positions, 128 closed, 401 increased, and 297 decreased. The institutional picture is therefore not unilaterally negative, but it is also not purely accumulative.

What to Watch

The first practical metric is the net margin. The latest value of 13.9% is the highest in the given series. For further data reading, it will be important whether the company stays near this level or returns closer to the weaker period of 9.8% from Q4 2025-03-31. Margins are key here because with a P/E of 110.7, the market tolerates smaller disappointments worse than with cheaper companies.

The second metric is free cash flow. The latest FCF of $245.2 million follows previous positive periods, but the series shows fluctuations: for example, $148.9 million in Q2 2024-09-30, $326.4 million in Q1 2025-06-30, and $199.5 million in Q3 2025-12-31. Stabilization of FCF around higher levels would support the fundamental thesis; a more significant drop would highlight the problem of FCF yield of 1%.

The third area is the technical score TSS 46.7. If the technicals moved above the more neutral area around 50, the gap between the strong FVS 91.4 and the overall score of 61.5 would narrow. Relative strength RS 52 is only slightly positive so far, so the data does not yet speak of a clear trend leader.

The fourth point is the model deviation of -10.6%. Since a positive value indicates room for growth, the current negative deviation says that the model does not see the stock as undervalued. A shift of this metric towards a neutral area would be important for whether the valuation begins to align more with the fundamentals.

The fifth area is public reports of insiders and institutions. Insider purchases of $40.9 million against sales of $5.5 million are a positive signal, while institutions show a more mixed picture: 109 new positions against 128 closed and 401 increased against 297 decreased. With institutional data, it is necessary to always account for a delay of approximately 45 days.

Risks

The main risk is valuation. A stock with a P/E of 110.7 and a P/S of 15.35 needs the company to continue delivering growth and quality earnings. If revenue growth of 7.3% slows or the net margin decreases, the market may start to reassess the premium it pays for the stock.

The second risk is low capital returns. ROIC of 4.4% and ROE of 3.1% are not in line with the image of an extremely profitable capital machine. This may be why the overall score of 61.5 lags behind FVS 91.4 and EQS 88.

The third risk is technical. TSS of 46.7 and a price 11.9% below the 52-week high show that the market has not yet sent as strong a trend signal as the fundamental data. The recent growth of about 11.3% over roughly 90 days improves this picture but does not eliminate it.

The fourth risk is the interpretation of smart-money data. WHS is 60, insider activity IAS 62.1, and institutional flow IFS 58. These are rather slightly positive values, not extremely strong signals. Additionally, the institutional count decreased by 22, and there were more closed positions than new ones.

How QMA Score Sees It

The QMA picture is ambiguous but readable. A composite score of 61.5 and a grade of B+ indicate that STERIS is an above-average title, but not a pure quantitative favorite. FVS 91.4, EQS 88, and XS 84 create a strong fundamental core: the company is growing, generating cash flow, and has a quality accounting profile.

Against this stands TSS 46.7, model deviation -10.6%, P/E 110.7, P/S 15.35, and FCF yield 1%. This is the main answer to the question of what holds the company back. The weakest link is not the latest income statement, but the combination of price, technicals, and capital efficiency.

The smart-money pillar is slightly supportive, not decisive. WHS 60, IAS 62.1, and IFS 58 show a slightly positive signal, with insider purchases stronger than institutional flow. The third-party consensus as of 2026-08-27 is positive: the average analyst estimate is $258.43 from 14 analysts, which is 9.1% above the last price of $236.77, and the rating distribution shows 12 positive ratings and 2 neutral. However, this remains a third-party estimate, not a QMA conclusion.

Overall, the data shows a quality healthcare company where fundamentals outpace the overall score. STERIS has a strong operational profile, but the market already charges a high price for it. That's why the stock is analytically interesting: it's not a simple story of cheap quality, but a test of whether growth, margins, and cash flow can justify a premium valuation.

This is an automated analytical and educational consideration by QMA Brain, not an investment recommendation. Past performance and historical data do not guarantee future results. Find the stock detail here: open stock detail in QMA.